Skip to content

Endosleeve in Adolescents

Safety and Efficacy of Endoscopic Sleeve Gastroplasty in Obese Children and Adolescents

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03778697
Enrollment
100
Registered
2018-12-19
Start date
2017-12-01
Completion date
2019-05-04
Last updated
2019-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Childhood

Brief summary

In this study, the investigators assess the safety and efficacy of endoscopic sleeve gastroplasty in adolescents with obesity.

Detailed description

Endoscopic bariatric therapy (EBT) is an emerging, rapidly evolving field that aims to serve as a middle ground between safe, albeit poorly effective medical weight loss strategies and drastic but effective bariatric surgery. Endoscopic sleeve gastroplasty (ESG) is a procedure that restricts the stomach to a sleeve-like configuration by utilizing full-thickness sutures that plicate the greater curvature of the stomach. Emerging data from adult populations shows an acceptable safety, tolerability and efficacy profile. Based on analysis that confirmed the safety and efficacy of ESG in adult patients who undergo the procedure under a standardized protocol and clinical care pathway, the investigators planned to study its effects on adolescents in a specialized center that offers surgical, endoscopic, and medical management of obesity under a standardized protocol and care pathway.

Interventions

Endoscopic full-thickness suture system to plicate the greater curvature of the stomach

Sponsors

New You Medical Center
CollaboratorUNKNOWN
King Saud University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
10 Years to 21 Years
Healthy volunteers
Yes

Inclusion criteria

* BMI that is \>120% of the 95th percentile for age and gender * Written informed assent/consent, with concomitant parental consent for patients aged ≤17 years

Exclusion criteria

* Age \<10 years * Age \>21 years * Presence of large hiatal hernia * Previous gastric surgery * Cognitive impairment

Design outcomes

Primary

MeasureTime frameDescription
Weight LossOne year% total weight loss
Adverse eventsOne yearAdverse events, including hospitalization, or unplanned intervention

Countries

Saudi Arabia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026